Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Recruiting now · Phase 1
Conditions studied: Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
In brief
Up to 40 evaluable women with known or suspected epithelial ovarian, fallopian tube, or primary peritoneal cancer will participate in two different imaging cohorts. The Biodistribution cohort will include up to 4 patients and the Dynamic cohort will include up to 36 patients. Human dosimetry will be calculated from the Biodistribution cohort. The Dynamic cohort date will evaluate preliminary information on uptake of \[18F\]FTT in gynecological cancer and compare with PARP-1 activity in tissue.
Key facts
- Study ID
- NCT02637934
- Run by
- Abramson Cancer Center at Penn Medicine
- People needed
- 35
- Starts
- 2016-01-14
- Expected to finish
- 2026-10-01
- Last updated by the study team
- 2026-04-07
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.